Journal
JOURNAL OF MEDICINAL CHEMISTRY
Volume 56, Issue 6, Pages 2178-2195Publisher
AMER CHEMICAL SOC
DOI: 10.1021/jm301783x
Keywords
-
Categories
Funding
- National Institute on Mental Health [MH063266]
- National Institute on Drug Abuse [DA09045, DA021002]
Ask authors/readers for more resources
kappa opioid receptors (KORs) belong to the G-protein-coupled class of receptors (GPCRs). They are activated by the endogenous opioid peptide dynorphin (DYN) and expressed at particularly high levels within brain areas implicated in modulation of motivation, emotion, and cognitive function. Chronic activation of KORs in animal models has maladaptive effects including increases in behaviors that reflect depression, the propensity to engage in drug-seeking behavior, and drug craving. The fact that KOR activation has such a profound influence on behaviors often triggered by stress has led to interest in selective KOR antagonists as potential therapeutic agents. This Perspective provides a description of preclinical research conducted in the development of several different classes of selective KOR antagonists, a summary of the clinical studies conducted thus far, and recommendations for the type of work needed in the future to determine if these agents would be useful as pharmacotherapies for neuropsychiatric illness.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available